Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. announced its unaudited financial results for the third quarter of 2025, showcasing a revenue of RMB 13.75 billion, marking a 3.58% increase compared to the same period last year. The net profit attributable to shareholders rose by 13.10% to RMB 543.72 million, although the net cash flow from operating activities was negative at RMB -2.05 billion. These results indicate a stable revenue growth and profitability, despite challenges in cash flow, which could impact the company’s operational liquidity and stakeholder confidence.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major player in the pharmaceutical industry, primarily engaged in the distribution and retail of pharmaceuticals and healthcare products. The company operates in the People’s Republic of China and has a significant presence in Hong Kong, focusing on providing medical and healthcare services.
Average Trading Volume: 5,562,333
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.35B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.